Transforming The Management Of Critical Bleeding and Clotting

HemoSonics is bringing to market a next-generation point-of-care diagnostic platform, the Quantra, that provides actionable information to guide the management of critical bleeding and clotting.

Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted selection and dosing of blood products in critical settings. We seek to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely and accurate information on coagulation status at the point of care, enabling clinicians to rapidly choose the right treatment, dramatically improving outcomes and lowering treatment costs.

Our Products

The Quantra™ is a rapid, easy-to-use, point-of-care diagnostic platform that fully characterizes and guides the management of critical bleeding.
Learn more.

Our Technology

Our patented SEER sonorheometry technology quantifies coagulation by measuring the evolving stiffness of clotting blood.
Learn more.

Our Leadership

Our team has a proven track record of successfully developing and bringing to market innovative medical devices.
Learn more.

Blood cells

Studies show that use of comprehensive point-of-care coagulation testing in surgical settings leads to:

Improved clinical outcomes

  • Fewer transfusions
  • Fewer complications

Reduced cost of care

  • Reduced blood product utilization
  • Shorter inpatient stays


Stago Group acquires HemoSonics LLC

The Stago group announced today that it has completed the acquisition of HemoSonics LLC, a company specialized in the development of innovative Point-of-Care testing solutions based in Charlottesville, VA, with facilities in Durham, NC (USA). With the acquisition of the patented SEER technology (Sonic Estimation of Elasticity via Resonance) and its associated QuantraTM Hemostasis Analyzer, Stago demonstrates its willingness to develop a Point-of-Care offering to complete its leadership in Haemostasis testing and beyond. This transaction provides Stago with expanded opportunities for future growth and is an important part of the company’s on-going efforts to diversify its portfolio of medical devices in an ever-changing healthcare environment. “This significant step makes us very proud to contribute to the management of healthcare costs and to the improvement of patients outcomes worldwide,” says Lionel Viret, Chairman of the Board. “Stago brings exceptional expertise in the field of Thrombosis and Hemostasis that will greatly advance our efforts to rapidly and effectively deliver a new standard of care for the management of bleeding in the critical care setting,” says Timothy Fischer, President and Chief Executing Officer of HemoSonics. Ferghana Partners acted as exclusive financial advisor to HemoSonics for this transaction. About Stago Leading player in the In-Vitro Diagnostics industry dedicated to the exploration of Thrombosis and Haemostasis, Stago develops and markets automated systems for blood analysis in coagulation. Created in 1945, Stago is fully dedicated to Haemostasis since 1962. Privately-owned and independent, Stago is headquartered in Asnières, France, with R&D, manufacturing and logistics activities mainly in Europe. Its products are available in 115 countries through a network of 20 subsidiaries and 94 distributors. Stago Group’s... read more

Anesthesia & Analgesia Profiles Quantra’s SEER Technology in Article of the Month and Podcast

Charlottesville, VA  – December 7, 2016 – The editorial staff of Anesthesia & Analgesia has chosen the article “A Novel Device for the Evaluation of Hemostatic Function in Critical Care Settings,” which details the Quantra™ Hemostasis Analyzer, as its Article of the Month featured on the journal’s home page. The article introduces the Quantra analyzer and the Surgical Cartridge and presents the results of analytical performance testing using a research version of the Quantra. These results demonstrate the ability of the Quantra and the Surgical Cartridge to rapidly and comprehensively characterize the key functional components of hemostasis. In addition, has conducted a podcast with Dr. Francesco Viola, Founder and Chief Scientific Officer of HemoSonics, about the article and the Quantra Hemostasis Analyzer. The interview can be found at: Contact Megan Shaw HemoSonics 434.260.0682... read more

Abstract on SEER Technology to be Presented at PGA

Charlottesville, VA – December 6, 2016– HemoSonics today announced the upcoming presentation of data at the Post Graduate Assembly in Anesthesiology (PGA) Meeting demonstrating the potential of the Quantra™ Hemostasis Analyzer to aid clinicians in identifying the need for transfusion of allogeneic blood products in major spine surgery. The conference will be held in New York, NY December 9 – 13, 2016. The reported study was conducted at the University of Virginia in Charlottesville, VA and compared results obtained with a research version of the Quantra™ Hemostasis Analyzer to equivalent rotational thromboelastometery (ROTEM™) and conventional laboratory parameters. The abstract “Predicting Cryoprecipitate and Platelet Transfusion During Major Spine Surgery with SEER Sonorheometry versus Rotational Thromboelastometry” authored by Dr. Bhiken Naik, Dr. Marcel Durieux, and Dr. Edward Nemergut, all faculty in the Department of Anesthesiology at the University of Virginia, showed significant differences in the Quantra measurements of Clot Stiffness, Platelet Contribution and Fibrinogen Contribution between the patients that received a transfusion and those that did not. The area under the Receiver Operative Curves (ROC), a measure of the performance of a diagnostic test, for Fibrinogen Contribution versus cryoprecipitate transfusion, Clot Stiffness versus cryoprecipitate-platelet transfusion, and Platelet Contribution versus platelet transfusions were 0.8, 0.79, and 0.8, respectively. These data indicate that the Quantra and SEER Sonorheometry may provide clinically relevant measurements that could be utilized to aid in the management of perioperative bleeding. Abstract Details Title: Predicting Cryoprecipitate and Platelet Transfusion During Major Spine Surgery with SEER Sonorheometry versus Rotational Thromboelastometry Authors: Naik, BI, Durieux, ME, Nemergut, EC Date: December 11, 2016, 9:30am Board:  P-9092 Contact Megan Shaw HemoSonics 434.260.0682... read more

HemoSonics’ Groundbreaking System for the Management of Critical Bleeding Presented in Four Articles in Anesthesia & Analgesia

Clinical Studies Showed Rapid and Comprehensive Measurement of Coagulation at the Point-of-Care Charlottesville, VA, September 20, 2016 – HemoSonics announced today the publication of four journal articles, accompanied by an editorial, in Anesthesia & Analgesia describing the first clinical experiences with the QuantraTM Hemostasis Analyzer, a groundbreaking system designed to transform and improve the management of critical bleeding. These papers introduce the device and describe the results of multi-center clinical studies involving more than 150 cardiac and spine surgery patients. The leading editorial highlights Quantra’s novel SEER Sonorheometry technology, which may provide significant advantages over existing systems. “The Quantra is a major leap forward in viscoelastic testing, as current hemostasis testing is limited by long result times and incomplete parameter measures,” said Dr. Bruce Spiess, Professor and Associate Chief for Research within the Department of Anesthesiology at the University of Florida and lead author of one of the papers. “These studies demonstrate that the Quantra provides clot time and clot stiffness results that correlate with existing technologies. In addition, the device delivers extremely important information through its Fibrinogen Contribution and Platelet Contribution measures that are not currently available in a rapid time frame. With the Quantra, we have a tool to help rapidly and accurately determine the cause of critical bleeding, enabling precise treatment and reducing unnecessary blood transfusions.” The Quantra and its Surgical Cartridge, the first in a series of test cartridges, were designed to facilitate quick and precise treatment of critical bleeding. These studies demonstrate the ability of the Quantra to monitor coagulation at the point of care in critical care settings and generate comprehensive results in... read more